LataMed AI Corp.

LataMed AI Corp. is a U.S.-based healthcare technology company focused on artificial intelligence-enabled analytics, telehealth infrastructure, and healthcare services coordination. The company’s operating structure includes a wholly owned Venezuelan subsidiary intended to support its Latin American healthcare technology and services platform.

— LataMed AI Corp.
%
Healthcare AI analytics40% Software and data tools for healthcare analytics, monitoring, and decision support.
Telehealth infrastructure25% Technology used to support remote care delivery and virtual healthcare workflows.
Care coordination services20% Services that organize patient pathways, referrals, and healthcare service delivery.
Healthcare technology IP15% Proprietary assets and intellectual property acquired for platform development.

The company appears to serve healthcare organizations and service providers that need software and operational tools...

  • Healthcare providersprimary

    Hospitals, clinics, and care networks that would use analytics, monitoring, and telehealth tools to improve care delivery.

  • Healthcare service operatorsprimary

    Organizations coordinating patient services and workflows that need software to manage care pathways and communications.

  • Latin American healthcare partnerssecondary

    Regional operators and counterparties in Latin America that may adopt localized healthcare technology and services.

  • Telehealth users and platformssecondary

    Customers needing virtual care infrastructure and related digital health applications.

LataMed AI Corp. is incorporated in the United States, but its stated operating focus is Latin America...

  • Headquartered in the United States
  • Operating focus on Latin America
  • Venezuelan subsidiary supports regional execution
  • Cross-border healthcare technology deployment
  • Local regulatory planning is important to market entry

The company is transitioning toward an AI-enabled healthcare technology and services model centered on Latin America...

01
Commercialize the healthcare AI platformshort-term

The company needs a marketable product and service offering to convert development work into revenue.

02
Build Latin American operating infrastructureshort-term

Regional execution depends on local operating entities, regulatory readiness, and market relationships.

03
Integrate acquired proprietary assetsmedium-term

The acquired IP and technology assets are the core inputs for the company’s platform strategy.

04
Raise external capitalshort-term

A development-stage healthcare technology business typically requires funding before scale is reached.

The company faces early-stage execution and financing risk because it is still building its healthcare technology...

critical

Insufficient liquidity and financing risk

The company states it does not have sufficient cash to operate at the current level for the next twelve months.

Scope
Operations and platform development
Materiality
high
high

Early-stage commercialization risk

The business is still in organizational development and has not generated revenue, so product-market fit is unproven.

Scope
Healthcare AI and telehealth offerings
Materiality
high
high

Cross-border regulatory risk

Operating in Latin America, including Venezuela, can involve local healthcare, data, and corporate compliance requirements.

Scope
Regional expansion
Materiality
medium
medium

Integration risk for acquired assets

The company acquired proprietary healthcare technology assets and must integrate them into its operating model.

Scope
Platform development and IP utilization
Materiality
medium
Revenue recognition under ASC 606
Affects when and how contract revenue is recorded
Intangible asset valuation and impairment
Could create impairment charges if expected value is not realized
Fair value measurements
Can affect balance sheet carrying values and expense recognition
Stock-based compensation
Can materially increase reported operating expenses

: 16.6.2026